Shares of Vascular Biogenics Ltd. (NASDAQ:VBLT) shot up 3.1% during trading on Monday . The stock traded as high as $4.11 and last traded at $4.04, with a volume of 116,110 shares trading hands. The stock had previously closed at $3.92.

Several research firms have recently commented on VBLT. Zacks Investment Research downgraded shares of Vascular Biogenics from a “hold” rating to a “sell” rating in a report on Thursday, May 5th. Chardan Capital reissued a “buy” rating on shares of Vascular Biogenics in a report on Tuesday, June 7th. Roth Capital reissued a “buy” rating and set a $22.00 price target on shares of Vascular Biogenics in a report on Thursday, June 9th. HC Wainwright began coverage on shares of Vascular Biogenics in a report on Tuesday, June 28th. They set a “buy” rating and a $11.00 price target on the stock. Finally, Piper Jaffray Cos. reissued a “buy” rating and set a $14.00 price target on shares of Vascular Biogenics in a report on Tuesday, June 7th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $13.67.

The stock’s 50-day moving average is $4.12 and its 200-day moving average is $3.71. The company’s market cap is $97.00 million.

Vascular Biogenics (NASDAQ:VBLT) last released its quarterly earnings data on Monday, August 15th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.09. On average, analysts predict that Vascular Biogenics Ltd. will post ($0.72) EPS for the current year.

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.